

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Frederic Becq et al.	Confirmation No.:	4276
Serial No.:	10/516,839	Art Unit:	1625
Filed:	March 4, 2005	Examiner:	Charanjit Aulakh
Customer No.:	21559		
Title:	Use of Benzo[c]Quinolizinium Derivatives for the Treatment of Diseases that are Linked to Smooth Muscle Cell Constriction		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY TO RESTRICTION REQUIREMENT

In reply to the Restriction Requirement that was mailed in connection with the above-captioned patent application on September 28, 2007, Applicants elect the invention of Group I, claims 6, 8-11, 17, 20 and, in part, claims 1-5, 7, 14-16, 18, 19, 21, and 22.

The election is made with traverse for the following reasons. All of the compounds of formulas (I), (Ia), and (Ib) are benzo[c]quinolizinium derivatives with several substituents, which may be independent of each other, or two consecutive substituents may form a ring comprising 5 to 10 carbon atoms as described on page 3, line 29 to line 30 of the English translation of the application. For example, compound 22 in claim 4 corresponds to a compound of formula (I) wherein R₃, R₄, R₅, and R₇ each represent a hydrogen atom, Y represents an amino group, and R₁ and R₂ together with C₁ and C₂ form a ring comprising 6 carbon atoms leading to a tetracyclic compound. In the same manner, compounds of formula (Ib) correspond to compounds of formula (I) wherein R₁, R₂, R₅, R₇, and Y each represent a specific substituent, and R₃ and R₄

together with C₃ and C₄ form a ring comprising 9 atoms leading to pentacyclic compounds.

Consequently, the compounds share a common core, benzo[c]quinolizinium, bearing independent substituents leading to tricyclic structures or substituents, which may form further rings leading to tetracyclic or pentacyclic structures.

Claim 1 also encompasses more generic formulas than formula I having a tricyclic structure and formulas Ia and Ib. Accordingly, if the Examiner maintains the Requirement, Applicants request that the Examiner provide additional Groups to address those compounds not covered by Groups I-III.

Although no fees are believed to be due, if there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: November 27, 2007

Susan M. Michaud
Susan M. Michaud, Ph.D.
Reg. No. 42,885

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045